PATENT CLAIM ANALYSIS

Application Number: 16302955
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-07
Patent Classification: ["514", "264100"]

Abstract:
The present invention provides, inter alia, methods, pharmaceutical compositions, and kits for treating or ameliorating the effects of a cancer in a subject, which cancer is refractory or resistant to non-ERK MAPK pathway inhibitor therapy. Also provided are methods for identifying a subject having cancer who would benefit from therapy with an ERK inhibitor and methods for inhibiting phosphorylation of RSK in a cancer cell that is refractory or resistant to a non-ERK MAPK pathway inhibitor.

Claim (Index 6):
A composition for treating a subject having an unresectable or metastatic BRAF600 mutation-positive melanoma, the composition comprising 600 mg of BVD-523 or a pharmaceutically acceptable salt thereof and optionally a pharmaceutically acceptable carrier, adjuvant, or vehicle.

Metadata:
- Claim Count in Document: 23.0
- Percentile: 98.0
- Lexical Diversity: 1.62745
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15105904', '16033953', '14770994', '15580991', '14473311']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.750492023417502
- 35 USC 102 Novelty (BERT): 0.603500973940185
- Combined Prediction Score: 0.7357929184697704
- Mean Citation Score: 391.568936
- Max Citation Score: 630.28436
- Similarity Product: 422.5373526602864

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test